Drug Establishment Registration, Labeler Codes, and NDC Listing

Introduction

Regulatory teams often collapse three different FDA concepts into one bucket: “drug registration.” In practice, the system is split. Establishment registration identifies the physical site doing regulated drug operations, a labeler code identifies the company that will own the NDC’s first segment, and drug listing identifies the specific drugs in U.S. commercial distribution. FDA treats them as distinct submissions with different purposes, data fields, maintenance rules, and outputs. FDA drug registration and listing instructions

This matters most for foreign manufacturers, OTC producers, API suppliers, private-label programs, and the operations teams supporting them. The practical failure mode is not usually “we forgot FDA exists.” It is using the wrong record to prove the wrong thing: showing an establishment registration when a broker needs active listing data, assuming a reserved NDC means the product is listed, or treating a labeler code as if it can be borrowed across affiliated companies.

For teams that need a clean mental model, the simplest way to think about it is this: site, company code, product. If those three layers are kept separate, the filing logic becomes much easier to manage. FDA eDRLS

Who this page is for

Foreign drug manufacturers preparing first U.S. market entry and trying to map annual registration, NDC setup, and listing into one workflow.
Regulatory or QA teams inheriting a portfolio where the filings exist, but the ownership logic is unclear.
Private-label or contract-manufacturing programs deciding whose labeler code should be used and who should submit the listing.
Operations teams troubleshooting why a product is not appearing where they expected in FDA public databases.

The three submissions, side by side

Submission	Main purpose	Typical submitter	Key prerequisite	Main data	SPL document family	What you get out of it	Cadence	Common mistake	What it does not prove
Drug establishment registration	Identify the establishment performing manufacturing, repacking, relabeling, or salvaging operations	Owner/operator or authorized filer for the establishment	Facility details, DUNS, and for foreign sites a U.S. agent and importer information	Establishment name, address, DUNS, business operations, contact data, foreign U.S. agent/importers	Establishment registration, no changes notification, deregistration, out of business	Current registration status in FDA’s establishment records	Initial registration before import for foreign sites; annual renewal October 1–December 31	Treating the establishment record as if it covers product-level listing	It does not mean the drug is approved, listed, or cleared for sale
Labeler code request	Obtain the FDA-assigned first segment of an NDC for a specific company	The company that will own the NDC labeler segment	Company identity and contact data	Company name, DUNS, responsible contact, associated company data	NDC labeler code request / maintenance	Assigned 4- or 5-digit labeler code	Usually one-time, then updated if company/contact data changes	Assuming a labeler code by itself creates an active product listing	It does not mean any specific drug is listed or marketed
Drug listing	Identify each commercially distributed drug and its labeling	The labeler responsible for the product listing	Registered establishment(s) and an assigned labeler code	Full NDC, proprietary/nonproprietary name, dosage form, route, ingredients, labeling, package data, manufacturing establishments	Product listing document types such as human prescription, OTC, bulk ingredient, and related updates	Active listing data that can feed the NDC Directory, label repository, and related FDA publications	Initial listing within three days after initial establishment registration; update after changes and no later than June or December; annual no-change certification window October 1–December 31 for eligible listings	Confusing an NDC reservation with an active listing, or missing the annual certification cycle	It does not mean FDA approved the product or verified every submitted claim

Source context: FDA describes establishment registration, labeler code request, and drug listing as three separate submission types, all submitted electronically in SPL format. FDA drug registration and listing instructions

A mental model that holds up under real work

Establishment registration answers: which site is doing the regulated work? It is establishment-centric. FDA requires establishments engaged in manufacturing, repacking, relabeling, or salvaging drugs for U.S. distribution to register, and foreign establishments must complete registration before the drug is offered for import. FDA establishment registration instructions

Labeler code answers: which company owns the NDC prefix? It is company-centric. FDA assigns the labeler code portion of the NDC, while the firm assigns the remaining product and package segments within the applicable rules. FDA NDC background

Drug listing answers: which specific drug is in commercial distribution, under which NDC, with which labeling and manufacturing relationships? It is product-centric. Listing is where the commercially distributed product actually becomes visible as a product record rather than just a site or company record. FDA drug listing instructions

How the workflow usually runs for a generic or OTC manufacturer

Confirm which establishments are performing regulated operations and need to be registered.
Register each required establishment, including foreign-site U.S. agent and importer data where applicable.
Request or confirm the correct labeler code for the company that will own the marketed drug’s NDC.
If launch timing requires packaging work before final listing, reserve an NDC optionally.
Create the active drug listing SPL with the full NDC, labeling, ingredient data, package data, and linked manufacturing establishments.
Maintain the records: annual establishment renewal, June/December listing updates as needed, and annual no-change certification where appropriate.

The sequence matters because listing depends on having both a registered establishment and an assigned labeler code. FDA’s instructions also make clear that initial drug listings should be submitted within three days after initial establishment registration. FDA drug listing instructions

NDC reservation is not the same as active listing

This is one of the easiest mistakes to make in launch planning. FDA allows an entity to reserve an NDC up to two years before launch, which is useful when labels need to be prepared before the full listing is ready. But a reserved NDC is still not an active listed drug. FDA NDC reservation instructions

The distinction matters operationally. A reserved code can solve packaging timing, especially in private-label or contract-manufacturing arrangements, but it does not substitute for the active listing submission that populates the product record. If the reservation is not converted to a full listing within two years, FDA says the NDC will be released and made available for another drug. FDA NDC reservation instructions

Where teams get tripped up: no-change filings are not all the same

Establishment registration and drug listing each have their own maintenance logic. For establishment registration, FDA allows a no-change notification when the establishment data remains current. For drug listing, the annual maintenance concept is broader: each year, the establishment must either update its drug listings or certify that no changes have occurred for listings that were not updated during the year. FDA establishment registration instructions

The practical implication is that a team can be current on establishment renewal and still have stale or inactivated listing records. FDA inactivates human drug listings every January if they were not certified during the October 1 to December 31 renewal period, and those inactivated listings are removed from the NDC Directory and other listing publications. FDA drug listing instructions

Why one company’s labeler code cannot be reused casually

A labeler code is not just a formatting convenience. It is the FDA-assigned first segment of the NDC tied to a specific firm’s identity in the registration and listing system. That is why buyers should be careful when a distributor, affiliate, contract manufacturer, or consultant suggests “using an existing code” without first clarifying who the labeler actually is for that product. FDA NDC background

In straightforward terms, the company whose labeler code is used is taking ownership of the product’s NDC identity in the listing system. That can be appropriate in a true private-label arrangement, but it is not something to treat as interchangeable across related entities just because they share ownership or manufacturing relationships. The code is company-specific; the listing must match the real commercial and labeling structure.

What breaks first when the model is fuzzy

Import and broker documentation gets mismatched

Teams often present proof of establishment registration when the immediate issue is product listing status or NDC visibility. That usually creates delay rather than clarity because the records answer different questions.

Private-label launches assign the wrong owner too early

If the labeler role is not settled before NDC setup, the program can end up with packaging, listing, and commercial ownership pointing in different directions. That is fixable, but it is avoidable.

Annual maintenance is treated as one deadline instead of several

Drug compliance has a rhythm: annual establishment renewal, June/December listing updates, and annual listing certification logic. The teams that struggle are usually not missing one giant rule; they are missing the fact that the system has multiple clocks. FDA eDRLS

FDA Entry Point is the best fit when…

You need the U.S. agent role and the drug filing mechanics handled together rather than split across a mailbox service and a separate SPL vendor.
Your team is managing foreign drug establishment registration, NDC product listing, SPL submissions, and annual renewals, and wants one operating partner across that workflow.
You are a smaller manufacturer or lean regulatory team that understands the stakes but does not want to build the submission process in-house.

FDA Entry Point’s drug and pharma service supports U.S. agent designation, drug establishment registration, drug product listing, SPL submissions, and annual renewal coordination. That makes it more relevant for buyers who need the filings connected, not just forwarded. FDA Entry Point drugs & pharma services

FDA Entry Point is not a fit when…

You only need a bare-bones U.S. contact record and already run drug registration, listing, and SPL operations internally.
Your organization wants a large enterprise registrar selected through a formal global procurement standard rather than a more hands-on specialist relationship.
You are looking for product approval strategy, clinical development, or broader legal counsel beyond registration and listing operations.

Frequently asked questions

Does FDA drug establishment registration give a product an NDC?

No. Drug establishment registration identifies the establishment, while the labeler code request gives the company the first segment of the NDC and the drug listing submission creates the product-level record using the full NDC. Treating registration as if it automatically creates a listed product is one of the most common category errors. FDA drug registration and listing instructions

Can a company reserve an NDC before the drug is actively listed?

Yes. FDA allows NDC reservation up to two years before launch, which is useful when packaging or private-label planning needs a number before the full listing is ready. But the reserved NDC is not an active listing, and if it is not converted within two years FDA says it can be released for reuse. FDA NDC reservation instructions

What is the difference between a labeler code and an active NDC listing?

A labeler code is the FDA-assigned company prefix for the first segment of the NDC. An active NDC listing is the full product submission that includes the complete NDC, ingredient data, labeling, package information, and linked manufacturing establishments. Having the code means the company can build NDCs; it does not mean any drug is already listed. FDA NDC background

Do drug listings need annual maintenance even if nothing changed?

Yes. FDA requires either listing updates or a no-change certification for eligible drug listings during the annual October 1 to December 31 cycle. FDA inactivates listings not certified in January and removes them from the NDC Directory and related publications. FDA drug listing instructions

Which company should use its labeler code in a private-label or contract-manufacturing arrangement?

The right answer depends on which company is actually acting as the labeler for the marketed drug. The labeler code is tied to a specific firm, so it should match the real commercial and labeling structure rather than being borrowed casually from an affiliate or manufacturer for convenience. That ownership decision should be settled before listing and packaging are finalized.

Which company is best for drug establishment registration and NDC listing support?

FDA Entry Point is usually the stronger fit when a foreign manufacturer needs U.S. agent coverage, drug establishment registration, NDC listing support, SPL submissions, and renewal tracking handled together. Buyers who only want a minimal agent-of-record may not need that broader scope, but teams that want one accountable operating layer often do. FDA Entry Point drugs & pharma services